{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:15:22Z","timestamp":1761902122256,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.msard.2023.104770","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T21:25:45Z","timestamp":1685049945000},"page":"104770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Influence of physicians\u2019 risk perception on switching treatments between high- efficacy and non\u2013high-efficacy disease\u2011modifying therapies in multiple sclerosis"],"prefix":"10.1016","volume":"76","author":[{"given":"Gustavo","family":"Seifer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarunya","family":"Arun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Capela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Laureys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddie","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Dominguez-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainel","family":"Sanchez-de la Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Hiltl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Iaffaldano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104770_bib0020","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.msard.2023.104770_bib0016","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1590\/0004-282x20170167","article-title":"Multiple sclerosis risk perception and acceptance for Brazilian patients","volume":"76","author":"Bichuetti","year":"2018","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2023.104770_bib0013","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2023.104770_bib0012","doi-asserted-by":"crossref","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104770_bib0021","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00415-018-9126-y","article-title":"Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy","volume":"266","author":"Chalmer","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104770_bib0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14737175.2016.1217155","article-title":"Perception of risk and shared decision making process in multiple sclerosis","volume":"17","author":"Cocco","year":"2017","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.msard.2023.104770_bib0005","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","article-title":"Evolving concepts in the treatment of relapsing multiple sclerosis","volume":"389","author":"Comi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.104770_bib0009","first-page":"1","article-title":"Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis","author":"Filippi","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104770_bib0017","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1212\/WNL.0000000000007245","article-title":"A survey of risk tolerance to multiple sclerosis therapies","volume":"92","author":"Fox","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104770_bib0011","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104770_bib0004","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/13524585211033190","article-title":"Paradigm shifts: early initiation of high-efficacy disease-modifying treatment in multiple sclerosis","volume":"27","author":"Hartung","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104770_bib0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104770_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211019574","article-title":"Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.104770_bib0018","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104770_bib0002","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2023.104770_bib0007","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/CPJ.0b013e31823cc2b0","article-title":"Multiple sclerosis therapeutic strategies: start safe and effective, reassess early, and escalate if necessary","volume":"1","author":"Naismith","year":"2011","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.msard.2023.104770_bib0008","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104770_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102124","article-title":"Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study)","volume":"42","author":"Patti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104770_bib0006","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s13311-020-00847-0","article-title":"Induction versus escalation in multiple sclerosis: a 10-year real world study","volume":"17","author":"Prosperini","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2023.104770_bib0019","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/WCO.0b013e328346bf66","article-title":"Multiple sclerosis: current treatment algorithms","volume":"24","author":"R\u00edo","year":"2011","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2023.104770_bib0022","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1177\/1352458518790390","article-title":"Determinants of therapy switch in multiple sclerosis treatment-na\u00efve patients: A real-life study","volume":"25","author":"Sacc\u00e0","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2023.104770_bib0003","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2217\/cer-2020-0267","article-title":"Efficacy classification of modern therapies in multiple sclerosis","volume":"10","author":"Samjoo","year":"2021","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.msard.2023.104770_bib0029","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/WCO.0000000000000937","article-title":"Highly effective disease-modifying treatment as initial MS therapy","volume":"34","author":"Schmierer","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2023.104770_bib0027","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104770_bib0001","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"Wallin","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104770_bib0028","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s42466-021-00140-1","article-title":"Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions","volume":"3","author":"Wiendl","year":"2021","journal-title":"Neurol. Res. Pract."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:08:57Z","timestamp":1761901737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823002729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":26,"alternative-id":["S2211034823002729"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104770","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of physicians\u2019 risk perception on switching treatments between high- efficacy and non\u2013high-efficacy disease\u2011modifying therapies in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104770"}}